{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:39:56Z","timestamp":1684863596877},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,1,17]],"date-time":"2009-01-17T00:00:00Z","timestamp":1232150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s11894-009-0004-8","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T13:14:52Z","timestamp":1232111692000},"page":"22-27","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of chronic hepatitis B: Are we ready for combination therapy?"],"prefix":"10.1007","volume":"11","author":[{"given":"Anil","family":"Seetharam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Lisker-Melman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,17]]},"reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D. Lavanchy","year":"2004","unstructured":"Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97\u2013107.","journal-title":"J Viral Hepat"},{"key":"4_CR2","unstructured":"Centers for Disease Control and Prevention: Viral hepatitis. Available at www.cdc.gov\/ncidod\/diseases\/hepatitis\/resource\/dz_burden02.htm . Accessed October 2008."},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"Y.F. Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521\u20131531.","journal-title":"N Engl J Med"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0168-8278(99)80118-4","volume":"30","author":"S. Locarnini","year":"1999","unstructured":"Locarnini S, Birch C: Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIVinfected patients. J Hepatol 1999, 30:536\u2013550.","journal-title":"J Hepatol"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.21290","volume":"44","author":"H.J. Yim","year":"2006","unstructured":"Yim HJ, Hussain M, Liu Y, et al.: Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006, 44:703\u2013712.","journal-title":"Hepatology"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20723","volume":"41","author":"M.N. Brunelle","year":"2005","unstructured":"Brunelle MN, Jacquard AC, Pichoud C, et al.: Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41:1391\u20131398.","journal-title":"Hepatology"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-2006-939758","volume":"26","author":"A. Bartholomeusz","year":"2006","unstructured":"Bartholomeusz A, Locarnini SA: Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006, 26:162\u2013170.","journal-title":"Semin Liver Dis"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/hep.510290340","volume":"29","author":"S.K. Ono-Nita","year":"1999","unstructured":"Ono-Nita SK, Kato N, Shiratori Y, et al.: YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999, 29:939\u2013945.","journal-title":"Hepatology"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2005.10.018","volume":"44","author":"S.K. Fung","year":"2006","unstructured":"Fung SK, Chae HB, Fontana RJ, et al.: Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006, 44:283\u2013290.","journal-title":"J Hepatol"},{"issue":"Suppl1","key":"4_CR10","first-page":"654A","volume":"46","author":"S. Han","year":"2007","unstructured":"Han S, Chang TT, Chao YC, et al.: Four-year entecavir treatment in nucleosidenaive HbeAg+ patients: results from studies ETV-022 and -901 [abstract 938]. Hepatology 2007, 46(Suppl 1):654A.","journal-title":"Hepatology"},{"issue":"Suppl1","key":"4_CR11","first-page":"290A","volume":"46","author":"P. Marcellin","year":"2007","unstructured":"Marcellin P, Buti M, Krastev Z, et al.: A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102 [abstract LB2]. Hepatology 2007, 46(Suppl 1):290A\u2013291A.","journal-title":"Hepatology"},{"issue":"Suppl1","key":"4_CR12","first-page":"861A","volume":"46","author":"E.J. Heathcote","year":"2007","unstructured":"Heathcote EJ, Gane E, DeMan R, et al.: A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103 [abstract LB6]. Hepatology 2007, 46(Suppl 1):861A.","journal-title":"Hepatology"},{"issue":"suppl1","key":"4_CR13","first-page":"558A","volume":"44","author":"R. Gish","year":"2006","unstructured":"Gish R, Chang TT, Lai CL, et al.: Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg(+) chronic hepatitis B infection: observations from antiviralnaive patients treated with entecavir (ETV) or lamivudine (LVD) [abstract 992]. Hepatology 2006, 44(suppl 1):558A.","journal-title":"Hepatology"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","volume":"133","author":"R.G. Gish","year":"2007","unstructured":"Gish RG, Lok AS, Chang TT, et al.: Entecavir therapy for up to 96 weeks in patients with HbeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437\u20131444.","journal-title":"Gastroenterology"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2007.08.079","volume":"133","author":"P. Lampertico","year":"2007","unstructured":"Lampertico P, Vigano M, Manenti E, et al.: Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133:1445\u20131451.","journal-title":"Gastroenterology"},{"key":"4_CR16","unstructured":"AIDS information available at http:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL.pdf ."},{"issue":"Suppl2","key":"4_CR17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2893.1997.tb00185.x","volume":"4","author":"N.V. Naoumov","year":"1997","unstructured":"Naoumov NV, Rossol S: Studies of interleukin-12 in chronic hepatitis B virus infection. J Viral Hepat 1997, 4(Suppl 2):87\u201391.","journal-title":"J Viral Hepat"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/135965350601100206","volume":"11","author":"S.G. Lim","year":"2006","unstructured":"Lim SG, Wai CT, Lee YM, et al.: A randomized, placebocontrolled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther 2006, 11:245\u2013253.","journal-title":"Antivir Ther"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","volume":"126","author":"M.G. Peters","year":"2004","unstructured":"Peters MG, Hann H, Martin P, et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91\u2013101.","journal-title":"Gastroenterology"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/gut.2005.077099","volume":"55","author":"J.E. Yeon","year":"2006","unstructured":"Yeon JE, Yoo W, Hong SP, et al.: Resistance to adefovir dipivoxil (ADV) in lamivudine resistant chronic hepatitis B patients with treated with ADV. Gut 2006, 55:1488\u20131495.","journal-title":"Gut"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/hep.21189","volume":"43","author":"Y.S. Lee","year":"2006","unstructured":"Lee YS, Suh DJ, Lim YS, et al.: Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006, 43:1385\u20131391.","journal-title":"Hepatology"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P. Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206\u20131217.","journal-title":"N Engl J Med"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2004.07.003","volume":"64","author":"F. Zoulim","year":"2004","unstructured":"Zoulim F: Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004, 64:1\u201315.","journal-title":"Antiviral Res"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.46.4.562","volume":"46","author":"S.W. Schalm","year":"2000","unstructured":"Schalm SW, Heathcote J, Cianciara J, et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000, 46:562\u2013568.","journal-title":"Gut"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0168-8278(01)00145-3","volume":"35","author":"G. Barbaro","year":"2001","unstructured":"Barbaro G, Zechini F, Pellicelli AM, et al.: Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001, 35:406\u2013411.","journal-title":"J Hepatol"},{"key":"4_CR26","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1086\/375085","volume":"36","author":"K. Yalcin","year":"2003","unstructured":"Yalcin K, Degertekin H, Yildiz F, Celik Y: Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003, 36:1516\u20131522.","journal-title":"Clin Infect Dis"},{"key":"4_CR27","first-page":"305","volume":"11","author":"H. Deng","year":"2003","unstructured":"Deng H, Zhao ZX, Xu QH, et al.: Therapy effect of lamivudine combination with alpha interferon on patients with chronic hepatitis B [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2003, 11:305\u2013308.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"Suppl2","key":"4_CR28","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0168-8278(08)60105-1","volume":"48","author":"P. Marcellin","year":"2008","unstructured":"Marcellin P, Piratvisuth T, Brunetto M, et al.: Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peg-interferon alfa-2a (40KD) with or without lamivudine: results of 4 year follow-up [abstract 103]. J Hepatol 2008, 48(Suppl 2):S46.","journal-title":"J Hepatol"},{"key":"4_CR29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1386-6346(02)00145-6","volume":"24","author":"S. Sugahara","year":"2002","unstructured":"Sugahara S, Ichida T, Yamagiwa S, et al.: Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res 2002, 24:346\u2013354.","journal-title":"Hepatol Res"},{"key":"4_CR30","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1128\/JVI.71.4.3236-3243.1997","volume":"71","author":"V.J. Cavanaugh","year":"1997","unstructured":"Cavanaugh VJ, Guidotti LG, Chisari FV: Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997, 71:3236\u20133243.","journal-title":"J Virol"},{"key":"4_CR31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2249.2002.01943.x","volume":"130","author":"H.F. Lohr","year":"2002","unstructured":"Lohr HF, Pingel S, Bocher WO, et al.: Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B: restoration by exogenous interleukin-12. Clin Exp Immunol 2002, 130:107\u2013114.","journal-title":"Clin Exp Immunol"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/hep.20888","volume":"42","author":"E.I. Rigopoulou","year":"2005","unstructured":"Rigopoulou EI, Suri D, Chokshi S, et al.: Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005, 42:1028\u20131036.","journal-title":"Hepatology"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-009-0004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-009-0004-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-009-0004-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T16:43:44Z","timestamp":1684860224000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-009-0004-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,17]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s11894-009-0004-8","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,17]]}}}